Vaccine Challenge Studies Could Shrink Phase III Trials - Aventis' Lindberg
Executive Summary
The use of vaccine challenge studies could reduce the size of Phase III trials, Aventis Pasteur Exec VP-Research & Development Alf Lindberg said at the World Vaccine Congress in Paris Sept. 19.
You may also be interested in...
Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO
Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials